Induction Chemotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine whether neoadjuvant chemotherapy with
cisplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields
improves progression free survival rates compared to chemoradiation therapy alone in locally
advanced cervical cancer.
Women in the experimental arm will receive neoadjuvant chemotherapy with cisplatin and
paclitaxel every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women
in the control arm will receive concurrent chemoradiation therapy alone.
286 patients will be recruited during 2 years, with 3 years of follow up period.